Nanomedicine Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Nanomedicine stocks.

Nanomedicine Stocks Recent News

Date Stock Title
Nov 19 AZN AstraZeneca’s Tagrisso recommended for approval in EU by CHMP for certain NSCLC
Nov 19 AZN CHMP recommends AstraZeneca’s Tagrisso for EU approval for NSCLC
Nov 18 AZN GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study
Nov 18 AZN AstraZeneca picks first Treg cell therapy from Quell Therapeutics partnership
Nov 18 AZN Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy?
Nov 18 AZN Is AstraZeneca PLC (AZN) the Best Immunotherapy Stock to Buy Now?
Nov 18 AZN Is AstraZeneca PLC (AZN) A Cheap NASDAQ Stock To Invest In Now?
Nov 15 AZN How analysts are reacting to RFK Jr. as Trump's HHS pick
Nov 15 AZN Pharma Stock Roundup: AZN, BAYRY's Earnings, ABBV's Pipeline Setback
Nov 15 AZN Vaccine stocks drop on concerns about RFK Jr. heading HHS (update)
Nov 15 AZN Analysts think Wall Street's reaction to the RFK Jr. news is 'overdone.' Sort of.
Nov 15 AZN Ouch: Why a Healthcare Selloff Really Hurts in Europe
Nov 15 AZN Jim Cramer Says This Tobacco Stock Is 'Undervalued' But He's Not Recommending It
Nov 15 AZN Heard on the Street: RFK Jr. Is Spooking Obesity Investors Too
Nov 15 AZN Trump’s RFK Jr. Pick Weighs on Vaccine Makers
Nov 15 AZN Stocks to Watch Friday: Alibaba, Domino's, Palantir, Ulta Beauty
Nov 15 AZN RFK Jr. News Hits Global Pharma Stocks
Nov 14 AZN Vaccine makers close lower amid reports RFK Jr may head HHS (update)
Nov 14 AZN Is AstraZeneca a Buy as It Eyes the Weight Loss Market?
Nov 14 AZN China has trapped the tiger of AstraZeneca’s growth
Nanomedicine

Nanomedicine is the medical application of nanotechnology. Nanomedicine ranges from the medical applications of nanomaterials and biological devices, to nanoelectronic biosensors, and even possible future applications of molecular nanotechnology such as biological machines. Current problems for nanomedicine involve understanding the issues related to toxicity and environmental impact of nanoscale materials (materials whose structure is on the scale of nanometers, i.e. billionths of a meter).Functionalities can be added to nanomaterials by interfacing them with biological molecules or structures. The size of nanomaterials is similar to that of most biological molecules and structures; therefore, nanomaterials can be useful for both in vivo and in vitro biomedical research and applications. Thus far, the integration of nanomaterials with biology has led to the development of diagnostic devices, contrast agents, analytical tools, physical therapy applications, and drug delivery vehicles.
Nanomedicine seeks to deliver a valuable set of research tools and clinically useful devices in the near future. The National Nanotechnology Initiative expects new commercial applications in the pharmaceutical industry that may include advanced drug delivery systems, new therapies, and in vivo imaging. Nanomedicine research is receiving funding from the US National Institutes of Health Common Fund program, supporting four nanomedicine development centers.Nanomedicine sales reached $16 billion in 2015, with a minimum of $3.8 billion in nanotechnology R&D being invested every year. Global funding for emerging nanotechnology increased by 45% per year in recent years, with product sales exceeding $1 trillion in 2013. As the nanomedicine industry continues to grow, it is expected to have a significant impact on the economy.

Browse All Tags